Electrolyte disorders secondary to venetoclax

Nils van der Lubbe, Pieternella J. Lugtenburg, Ewout J. Hoorn*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Downloads (Pure)


Emerging cancer drugs introduce new forms of nephrotoxicity that may also present as electrolyte disorders. Here, we report a patient with non-Hodgkin lymphoma who developed severe hypokalaemia with concurrent hypophosphataemia, hypocalcaemia and hypomagnesaemia secondary to venetoclax. Although electrolyte disorders have been reported during treatment with venetoclax, these were ascribed to tumour lysis prophylaxis. Based on the temporal relationship and urinary studies, we show that venetoclax can cause these electrolyte disorders, likely through an effect on the proximal and distal convoluted tubule. In patients treated with venetoclax, we recommend close monitoring of electrolytes and avoiding co-medication that can contribute to electrolyte disorders.

Original languageEnglish
Pages (from-to)1272-1274
Number of pages3
JournalClinical Kidney Journal
Issue number4
Publication statusPublished - Apr 2021

Bibliographical note

Publisher Copyright:
VC The Author(s) 2020.


Dive into the research topics of 'Electrolyte disorders secondary to venetoclax'. Together they form a unique fingerprint.

Cite this